Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kagawa Macula Cohort Study
NCT02321267Phase 4Unknown
- Sponsor
- Kagawa University
- Start
- Dec 2014
- Primary completion
- Dec 2024
- Modality
- Small Interfering RNA (siRNA), Fc-Fusion Proteins, Antisense DNA
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab + sham injection, aflibercept, pegaptanib sodium, verteporfin in age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), Central Serous Chorioretinopathy (CSCR), choroidal neovascularization (CNV), sponsored by Kagawa University. Status: unknown.
02
Drugs
ranibizumab + sham injectionafliberceptpegaptanib sodiumverteporfin
03
Conditions
age-related macular degeneration (AMD)polypoidal choroidal vasculopathy (PCV)retinal angiomatous proliferation (RAP)Central Serous Chorioretinopathy (CSCR)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02321267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321267.